MedKoo Biosciences

Semaglutide
new

featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581055

CAS#: 910463-68-2 (free base)

Description: Semaglutide is a glucagon-like peptide-1 receptor agonist. It reduces food intake by lowering appetite and slowing down digestion in the stomach, helping to reduce body fat. It reduces hunger, food craving and body fat.

Chemical Structure

Semaglutide

CAS# 910463-68-2 (free base)

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 581055
Name: Semaglutide
CAS#: 910463-68-2 (free base)
Chemical Formula: C187H291N45O59
Exact Mass: 4,111.12
Molecular Weight: 4,113.640
Elemental Analysis: C, 54.60; H, 7.13; N, 15.32; O, 22.95

Price and Availability

Size	Price	Availability
10mg	USD 150	Ready to ship
25mg	USD 250	Ready to ship
50mg	USD 450	Ready to ship
100mg	USD 750	Ready to ship
200mg	USD 1350	Ready to ship
500mg	USD 2950	Ready to ship
1g	USD 4850	Ready to ship
2g	USD 8650	Ready to ship
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Related CAS #: 910463-68-2 (free base), Unknown (acetate),

Synonym: NN9535; NN-9535; NN 9535; Ozempic; Semaglutide; NNC 0113-0217; NNC-0113-0217; NNC0113-0217

IUPAC/Chemical Name: L-Histidyl-2-methylalanyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-alpha-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-(N-(17-carboxy-1-oxoheptadecyl)-L-gamma-glutamyl-2-(2-(2-aminoethoxy)ethoxy)acetyl-2-(2-(2-aminoethoxy)ethoxy)acetyl)-L-lysyl-L-alpha-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginylglycine

InChi Key: DLSWIYLPEUIQAV-CCUURXOWSA-N

InChi Code: InChI=1S/C187H291N45O59/c1-18-105(10)154(180(282)208-108(13)159(261)216-133(86-114-89-200-119-50-40-39-49-117(114)119)170(272)218-129(82-102(4)5)171(273)228-152(103(6)7)178(280)215-121(53-44-72-199-186(192)193)162(264)201-91-141(242)209-120(52-43-71-198-185(190)191)161(263)204-94-151(257)258)230-172(274)131(83-111-45-33-31-34-46-111)219-167(269)126(64-69-149(253)254)214-166(268)122(51-41-42-70-195-144(245)98-290-79-78-289-76-74-197-145(246)99-291-80-77-288-75-73-196-139(240)66-61-127(183(285)286)211-140(241)54-37-29-27-25-23-21-19-20-22-24-26-28-30-38-55-146(247)248)212-158(260)107(12)206-157(259)106(11)207-165(267)125(60-65-138(189)239)210-142(243)92-202-163(265)123(62-67-147(249)250)213-168(270)128(81-101(2)3)217-169(271)130(85-113-56-58-116(238)59-57-113)220-175(277)135(95-233)223-177(279)137(97-235)224-179(281)153(104(8)9)229-174(276)134(88-150(255)256)221-176(278)136(96-234)225-182(284)156(110(15)237)231-173(275)132(84-112-47-35-32-36-48-112)222-181(283)155(109(14)236)227-143(244)93-203-164(266)124(63-68-148(251)252)226-184(287)187(16,17)232-160(262)118(188)87-115-90-194-100-205-115/h31-36,39-40,45-50,56-59,89-90,100-110,118,120-137,152-156,200,233-238H,18-30,37-38,41-44,51-55,60-88,91-99,188H2,1-17H3,(H2,189,239)(H,194,205)(H,195,245)(H,196,240)(H,197,246)(H,201,264)(H,202,265)(H,203,266)(H,204,263)(H,206,259)(H,207,267)(H,208,282)(H,209,242)(H,210,243)(H,211,241)(H,212,260)(H,213,270)(H,214,268)(H,215,280)(H,216,261)(H,217,271)(H,218,272)(H,219,269)(H,220,277)(H,221,278)(H,222,283)(H,223,279)(H,224,281)(H,225,284)(H,226,287)(H,227,244)(H,228,273)(H,229,276)(H,230,274)(H,231,275)(H,232,262)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,285,286)(H4,190,191,198)(H4,192,193,199)/t105-,106-,107-,108-,109+,110+,118-,120-,121-,122-,123-,124-,125-,126-,127+,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,152-,153-,154-,155-,156-/m0/s1

SMILES Code: CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	By mimicking the action of the incretin glucagon-like peptide-1 (GLP-1), Semaglutide increases the production of insulin. It also appears to enhance growth of pancreatic beta cells. Additionally, it inhibits the production of glucagon.
In vitro activity:	Semaglutide protects against 6-OHDA cytotoxicity by increasing autophagy flux and decreasing oxidative stress as well as mitochondrial dysfunction in SH-SY5Y cells. Semaglutide may be represent a promising treatment for Parkinson's disease. Reference: Parkinsons Dis. 2022 Jul 13;2022:6813017. https://pubmed.ncbi.nlm.nih.gov/35873704/
In vivo activity:	Semaglutide has ameliorative effect against cisplatin- induced cardiotoxicity via modulation of mitochondrial functions, dynamics, biogenesis, apoptosis, and redox status pathways. Semaglutide treatment normalized dysregulated mitochondrial function and dynamics, redox status and suppressed mitophagy and apoptosis in male rats with cisplatin-induced cardiotoxicity treated with semaglutide. Reference: Cell Biochem Funct. 2023 Jun;41(4):450-460. https://pubmed.ncbi.nlm.nih.gov/37051656/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMSO	5.0	1.22

Preparing Stock Solutions

The following data is based on the product molecular weight 4113.640000000000000000000000000000 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Liu DX, Zhao CS, Wei XN, Ma YP, Wu JK. Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress. Parkinsons Dis. 2022 Jul 13;2022:6813017. doi: 10.1155/2022/6813017. PMID: 35873704; PMCID: PMC9300292. 2. Chang YF, Zhang D, Hu WM, Liu DX, Li L. Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis. J Clin Neurosci. 2020 Nov;81:234-239. doi: 10.1016/j.jocn.2020.09.054. Epub 2020 Oct 14. PMID: 33222922. 3. Atef MM, Hafez YM, El-Deeb OS, Basha EH, Ismail R, Alshenawy H, El-Esawy RO, Eltokhy AK. The cardioprotective effect of human glucagon-like peptide-1 receptor agonist (semaglutide) on cisplatin-induced cardiotoxicity in rats: Targeting mitochondrial functions, dynamics, biogenesis, and redox status pathways. Cell Biochem Funct. 2023 Jun;41(4):450-460. doi: 10.1002/cbf.3795. Epub 2023 Apr 12. PMID: 37051656. 4. Aranäs C, Edvardsson CE, Shevchouk OT, Zhang Q, Witley S, Blid Sköldheden S, Zentveld L, Vallöf D, Tufvesson-Alm M, Jerlhag E. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine. 2023 Jul;93:104642. doi: 10.1016/j.ebiom.2023.104642. Epub 2023 Jun 7. PMID: 37295046; PMCID: PMC10363436.
In vitro protocol:	1. Liu DX, Zhao CS, Wei XN, Ma YP, Wu JK. Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress. Parkinsons Dis. 2022 Jul 13;2022:6813017. doi: 10.1155/2022/6813017. PMID: 35873704; PMCID: PMC9300292. 2. Chang YF, Zhang D, Hu WM, Liu DX, Li L. Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis. J Clin Neurosci. 2020 Nov;81:234-239. doi: 10.1016/j.jocn.2020.09.054. Epub 2020 Oct 14. PMID: 33222922.
In vivo protocol:	1. Atef MM, Hafez YM, El-Deeb OS, Basha EH, Ismail R, Alshenawy H, El-Esawy RO, Eltokhy AK. The cardioprotective effect of human glucagon-like peptide-1 receptor agonist (semaglutide) on cisplatin-induced cardiotoxicity in rats: Targeting mitochondrial functions, dynamics, biogenesis, and redox status pathways. Cell Biochem Funct. 2023 Jun;41(4):450-460. doi: 10.1002/cbf.3795. Epub 2023 Apr 12. PMID: 37051656. 2. Aranäs C, Edvardsson CE, Shevchouk OT, Zhang Q, Witley S, Blid Sköldheden S, Zentveld L, Vallöf D, Tufvesson-Alm M, Jerlhag E. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine. 2023 Jul;93:104642. doi: 10.1016/j.ebiom.2023.104642. Epub 2023 Jun 7. PMID: 37295046; PMCID: PMC10363436.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Røder ME. Clinical potential of treatment with semaglutide in type 2 diabetes patients. Drugs Context. 2019 Dec 2;8:212585. doi: 10.7573/dic.212585. eCollection 2019. Review. PubMed PMID: 31844422; PubMed Central PMCID: PMC6905643. 2: Pearson S, Kietsiriroje N, Ajjan RA. Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date. Diabetes Metab Syndr Obes. 2019 Dec 2;12:2515-2529. doi: 10.2147/DMSO.S229802. eCollection 2019. Review. PubMed PMID: 31819577; PubMed Central PMCID: PMC6897065. 3: Oral semaglutide (Rybelsus) for type 2 diabetes. Med Lett Drugs Ther. 2019 Oct 21;61(1583):166-168. Review. PubMed PMID: 31770356. 4: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548574/ PubMed PMID: 31643889. 5: Pharmacoeconomic Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the treatment of adults patients with type 2 diabetes mellitus to improve glycemic control, in combination with metformin (second-line treatment), and in combination with metformin and sulfonylurea (third-line treatment) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK543966/ PubMed PMID: 31305974. 6: Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with metformin (second-line treatment), and in combination with metformin and sulfonylurea (third-line treatment) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK544012/ PubMed PMID: 31305971. 7: CADTH Canadian Drug Expert Committee Recommendation: Semaglutide (Ozempic — Novo Nordisk Canada Inc.): Indication: Diabetes mellitus, type 2 to improve glycemic control [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK543396/ PubMed PMID: 31287630. 8: Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019 Apr 12;10:155. doi: 10.3389/fendo.2019.00155. eCollection 2019. Review. PubMed PMID: 31031702; PubMed Central PMCID: PMC6474072. 9: Gomez-Peralta F, Abreu C. Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy. Drug Des Devel Ther. 2019 Feb 20;13:731-738. doi: 10.2147/DDDT.S165372. eCollection 2019. Review. PubMed PMID: 30863012; PubMed Central PMCID: PMC6388990. 10: Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising antiobesity drug. Obes Rev. 2019 Jun;20(6):805-815. doi: 10.1111/obr.12839. Epub 2019 Feb 15. Review. PubMed PMID: 30768766. 11: Aroda VR, Ahmann A, Cariou B, Chow F, Davies MJ, Jódar E, Mehta R, Woo V, Lingvay I. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019 Oct;45(5):409-418. doi: 10.1016/j.diabet.2018.12.001. Epub 2019 Jan 4. Review. PubMed PMID: 30615985. 12: Hedrington MS, Davis SN. Oral semaglutide for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2019 Feb;20(2):133-141. doi: 10.1080/14656566.2018.1552258. Epub 2018 Nov 30. Review. PubMed PMID: 30499733. 13: Coon SA, Crannage EF, Kerwin LC, Guyton JE. Semaglutide once-weekly: improved efficacy with a new safety warning. Expert Rev Clin Pharmacol. 2018 Nov;11(11):1061-1072. doi: 10.1080/17512433.2018.1534201. Epub 2018 Oct 16. Review. PubMed PMID: 30296182. 14: Goldenberg RM, Steen O. Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes. Can J Diabetes. 2019 Mar;43(2):136-145. doi: 10.1016/j.jcjd.2018.05.008. Epub 2018 Jun 5. Review. PubMed PMID: 30195966. 15: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK500980/ PubMed PMID: 30000039. 16: Tuchscherer RM, Thompson AM, Trujillo JM. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes. Ann Pharmacother. 2018 Dec;52(12):1224-1232. doi: 10.1177/1060028018784583. Epub 2018 Jun 22. Review. PubMed PMID: 29932006. 17: Hall S, Isaacs D, Clements JN. Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. Clin Pharmacokinet. 2018 Dec;57(12):1529-1538. doi: 10.1007/s40262-018-0668-z. Review. PubMed PMID: 29915923. 18: Hedrington MS, Tsiskarishvili A, Davis SN. Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes. Expert Opin Biol Ther. 2018 Mar;18(3):343-351. doi: 10.1080/14712598.2018.1439014. Epub 2018 Feb 15. Review. PubMed PMID: 29431519. 19: Dhillon S. Semaglutide: First Global Approval. Drugs. 2018 Feb;78(2):275-284. doi: 10.1007/s40265-018-0871-0. Review. PubMed PMID: 29363040. 20: Tan X, Cao X, Zhou M, Zou P, Hu J. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2017 Sep;26(9):1083-1089. doi: 10.1080/13543784.2017.1360274. Epub 2017 Aug 2. Review. PubMed PMID: 28741970.

Your view history

Semaglutide new featured